Amadix is a biotechnology company focused on the development and commercialization of innovative cancer diagnostic technologies that address unmet medical needs in oncology. The company aims to enhance early cancer detection through non-invasive methods, significantly improving patient outcomes and reducing the complications associated with traditional invasive procedures like tumor biopsies. Amadix's flagship product, Colofast, is a non-invasive blood test designed for the screening of colorectal cancer and advanced adenoma diagnosis, targeting the high mortality rate associated with this disease. The company is committed to validating its products through international multicenter studies to ensure clinical efficacy before global commercialization. The team at Amadix comprises experienced professionals with extensive backgrounds in oncology diagnostics, the pharmaceutical industry, and biotechnology, supported by an independent board of advisors with deep expertise in oncology and diagnostics, guiding the company's strategic and commercial efforts.
Transbiomed is a biotechnology company based in Barcelona, Spain, specializing in non-invasive molecular diagnostic therapies. The company has developed a urine test aimed at the early diagnosis of prostate cancer, offering a potential alternative to traditional biopsy methods. Transbiomed is currently seeking funding to initiate clinical validation of its innovations in various hospitals across Spain. The firm focuses on biomarker discovery and development, advancing its products through industrial prototyping, final design, and pivotal clinical trials, with the intention of licensing its technology to larger pharmaceutical companies for commercialization.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.